Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
Become a Member | Sign in
Home>Resources>White Papers>This White Paper
  White Papers
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
Potential Treatment for Life-Threatening Viral Infections Revealed
The findings point to new therapies for Dengue, West Nile and Ebola.
World’s First Therapeutic Venom Database
Open-source library describes nearly 43,000 effects on the human body.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Potential Persistent Tuberculosis Treatment
Researchers have discovered several first-in-class compounds that target hidden TB infections by attacking a critical process the bacteria use to survive in the hostile environment of the lungs.
Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
The Do’s and Don’ts of SPR Experiments
Surface Plasmon Resonance (SPR) is a technique that is becoming more widely used, particularly by anyone who wants to obtain accurate on (association) and off (dissociation) rates for biomolecular binding.
Long-Sought Protein Sensor for the ‘Sixth Sense’ Discovered
In a study led by scientists from The Scripps Research Institute (TSRI)the sensor protein for propioception has been identified.
New Anti-Malarial Drug Screening Model
University of South Florida researchers demonstrate novel chemogenomic profiling to identify drug targets for the most lethal strain of malaria.
Shedding Light on “Dark” Cellular Receptors
UNC and UCSF labs create a new research tool to find homes for two orphan cell-surface receptors, a crucial step toward finding better therapeutics and causes of drug side effects.
Scroll Up
Scroll Down

Use of a Label-Free Platform in a preclinical Contract Research Organization Environment
Bookmark and Share

Caliper Life Sciences

Caliper Discovery Alliances & Services (CDAS) is a Contract Research Organization offering comprehensive in vitro and in vivo preclinical contract research services. Their offering is articulated around different platforms including Target Validation with the creation of transgenic animals, Assay Development, Screening, Safety Pharmacology, Biochemical and Functional cell based profiling, Drug Efficacy in disease models and non-invasive small animal Optical Imaging.

NovaScreen Biosciences, now part of CDAS, pioneered receptor profiling studies in the early 1990’s and has established a best in class safety pharmacology platform with a large number of GPCR binding assays. Functional studies are very complementary to affinity-based radioligand assays as they provide very valuable information on the way a drug interacts with a GPCR target.

Using CDAS GPCRFunctional™ programs, you can determine if a drug is an activator or an inhibitor or what its potency and efficacy are for a given GPCR target. Understanding drug functionality is also an important benefit of functional studies and you can for example identify allosteric modulators that are generally difficult to identify using orthosteric ligand-based radioligand binding assays.

Further Information

Related Content

Caliper LS Receives $1.1 Million Task Order from the EPA's ToxCast™ Screening Program
This task order was issued pursuant to a contract that Caliper was awarded by the EPA in April 2007 under the ToxCast program.
Wednesday, August 20, 2008
Caliper Life Sciences Forms Alliance with Horizon Discovery
CDAS expands offering to include screening for targeted cancer drugs using genetically-defined in-vitro human disease models.
Thursday, April 10, 2008
Caliper Life Sciences Awarded EPA Contract
Caliper Discovery Alliances and Services unit will test environmental chemicals under EPA’s ToxCast research program.
Tuesday, April 10, 2007
Caliper Life Sciences Launches Drug Discovery and Development Services Business
Caliper combines in vitro and in vivo services of Novascreen Biosciences and Xenogen Biosciences to form Discovery Alliances & Services.
Tuesday, January 09, 2007
Caliper Strengthens Distribution Channels in China, Hong Kong and India
Leading international distributors expand customer access to Caliper microfluidics and drug discovery technologies.
Monday, February 13, 2006
Caliper Completes Acquisition of NovaScreen
The acquisition combines NovaScreen's screening, profiling and assay development services with Caliper's LabChip® and liquid handling products.
Thursday, October 06, 2005
Caliper Technologies expands Caliper 250 system

Monday, March 10, 2003
Caliper cut's Amphora Discovery's purchase obligations

Tuesday, December 17, 2002
Zymark Supplies HTS Systems to Vertex Pharmaceuticals

Tuesday, October 15, 2002

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos